ArticleAntimicrobial agents and chemotherapy2005
Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- An in silico analysis of rpoB mutations to affect Chlamydia trachomatis sensitivity to rifamycin.Journal, genetic engineering & biotechnology · 2022Article
- An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.Annals of clinical microbiology and antimicrobials · 2021Review
- Generation of Tetracycline and Rifamycin ResistantFrontiers in microbiology · 2021Article
- Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis.Journal of visualized experiments : JoVE · 2020Article
- Article
- Interaction of genotype and diet on small intestine microbiota of Japanese quail fed a cholesterol enriched diet.Scientific reports · 2018Article
- Whole-genome enrichment and sequencing of Chlamydia trachomatis directly from clinical samples.BMC infectious diseases · 2014Article
- Water-filtered infrared a irradiation in combination with visible light inhibits acute chlamydial infection.PloS one · 2014Article
- Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.Antimicrobial agents and chemotherapy · 2012Article
- Genomic stability of genotyping markers in Chlamydia trachomatis.Frontiers in cellular and infection microbiology · 2012Article
- Generation of targeted Chlamydia trachomatis null mutants.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Antibiotic resistance in Chlamydiae.Future microbiology · 2010Review
- Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro.Antimicrobial agents and chemotherapy · 2009Article
- Identification of concomitant infection with Chlamydia trachomatis IncA-negative mutant and wild-type strains by genomic, transcriptional, and biological characterizations.Infection and immunity · 2008Article
- Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection.Antimicrobial agents and chemotherapy · 2008Article
- Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.Antimicrobial agents and chemotherapy · 2006Article
- In vivo and in vitro studies of Chlamydia trachomatis TrpR:DNA interactions.Molecular microbiology · 2006Article
- In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2006Article
- Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection.Antimicrobial agents and chemotherapy · 2006Article
- Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stable, homotypic mutants of Chlamydia trachomatis for which MICs of rifampin and rifalazil are elevated were isolated by serial passage at sub-MIC concentrations of these compounds. An alternative approach, in which Chlamydia cells were incubated and subsequently passaged three times, all in the presence of the selective agent at concentrations above the MIC, appeared to be a more effective means of selecting for mutants. In every instance where an elevation in the MIC occurred, one or more mutations in the rpoB gene, encoding the rifampin binding site, were detected. With one exception, all rpoB mutants that contained a single mutation conferred lower levels of resistance than mutants containing multiple mutations. Some rpoB mutations conferred very high levels of resistance to rifampin, up to 512 mug/ml. In all cases, mutants remained susceptible to concentrations of rifalazil at or below 0.064 microg/ml. Thus, rifalazil, a compound that is extremely potent against Chlamydia wild-type cells (MIC of 0.00025 microg/ml), may also protect against the selection of mutants at physiologically achievable concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.